Health Care Facilities

Oncology Institute

Oncology Institute released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 147.44 M (forecast USD 144.47 M), actual EPS USD -0.0283 (forecast USD -0.09)

Oncology Institute to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 143.24 M, EPS USD -0.0775

Oncology Institute released FY2025 annual earnings on March 12 After-Market EST, actual revenue USD 502.73 M (forecast USD 500.58 M), actual EPS USD -0.5444 (forecast USD -0.5875)

Oncology Institute released FY2025 Q4 earnings on March 12 After-Market EST, actual revenue USD 141.96 M (forecast USD 139.79 M), actual EPS USD -0.074 (forecast USD -0.09)

Oncology Institute to Release FY2025 Q4 Earnings on March 12 After-Market EST, Forecast Revenue USD 139.78 M, EPS USD -0.09

Oncology Institute released FY2025 9 Months Earnings on November 13 After-Market EST, actual revenue USD 360.77 M, actual EPS USD -0.5013

Oncology Institute released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 136.56 M (forecast USD 122.63 M), actual EPS USD -0.1693 (forecast USD -0.1133)

Oncology Institute to Release FY2025 Q3 Earnings on November 13 After-Market EST, Forecast Revenue USD 122.63 M, EPS USD -0.1133

LeBoyer Reiterates Hold Rating on Oncology Institute

Larson Covers Healthcare Industry Stocks Performance

Oncology Institute released FY2025 Semi-Annual earnings on August 13 After-Market EST, actual revenue USD 224.21 M, actual EPS USD -0.3529

Oncology Institute released FY2025 Q2 earnings on August 13 After-Market EST, actual revenue USD 119.8 M (forecast USD 113.17 M), actual EPS USD -0.1824 (forecast USD -0.12)

Oncology Institute to release FY2025 Q2 earnings on August 13 After-Market EST, forecast revenue USD 113.17 M, EPS USD -0.12

Oncology Institute Inc applies for up to $50 million shelf registration

Brad Hively sells Oncology Institute shares

M33 Growth I L.P. reports disposition of common stock of Tumor Research Institute

BTIG Grants Buy Rating to Tumor Research Institute

Oncology Institute released FY2025 Q1 earnings on May 14 After-Market EST, actual revenue USD 104.41 M, actual EPS USD -0.2099

Tumor Institute to Present High-Value Cancer Care Model at ASCO Annual Meeting

Oncology Institute to Release FY2025 Q1 Earnings Report on May 14 After-Market EST

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

NAVN

CLSK

Wall Street analysts updated price targets for several stocks. BTIG raised Oncology Institute's target to $8, while Piper Sandler kept a Neutral rating. JP Morgan increased Victoria's Secret's target to $88 and lowered Insmed's to $179. DA Davidson cut Guidewire Software's target to $222. Chardan Capital raised CleanSpark's target to $19 but cut Hyperion DeFi's to $7.30. Rosenblatt raised Navan's target to $24, Needham raised Sportradar's to $23, and Ascendiant cut Plus Therapeutics' and Cingulate's targets.

benzinga_article

Navan

CleanSpark

Cingulate

Plus Therapeutics

Hyperion DeFi

Guidewire Software

Victorias Secret

Sportradar Group AG

Insmed

Tradr 2X Long CLSK Daily ETF

Oncology Institute - CW22

CLEANSPARK INC C/WTS 29/12/2028 (TO PUR COM)

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM)

Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday

SBIO

LABU

GatePass Capital LLC has invested $1.28 million in The Oncology Institute, Inc. by acquiring 360,000 shares. Other hedge funds have also adjusted their holdings in TOI. Analysts have mixed ratings on the stock, with a consensus rating of 'Moderate Buy' and a target price of $7.00. The stock opened at $4.59, with a market cap of $453.68 million. The Oncology Institute reported better-than-expected earnings, with revenue of $147.44 million for the last quarter.

Market Beat

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

VG Health

SPDR S&P Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

SPDR S&P Health

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

iShares US Healthcare Providers

iShares Biotechnology ETF

Goldman Sachs

JPMorgan Chase

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

GatePass Capital LLC Invests $1.28 Million in The Oncology Institute, Inc. $TOI

Tiff Advisory Services LLC reduced its stake in The Oncology Institute, Inc. (NASDAQ:TOI) by 77.2% in Q4, now holding 195,569 shares. Other institutional investors also adjusted their positions. The stock opened at $4.59, with a market cap of $453.68 million. The Oncology Institute reported earnings of ($0.02) per share, exceeding estimates. Analysts have mixed ratings, with target prices ranging from $5.00 to $8.00.

Tiff Advisory Services LLC Reduces Position in The Oncology Institute, Inc. $TOI

Jorey Chernett, a major shareholder of Oncology Institute (NASDAQ:TOI), purchased 5,000 shares at $4.05 each, totaling $20,250. Following this transaction, Chernett owns 10,534,358 shares valued at approximately $42.66 million. This acquisition represents a 0.05% increase in his holdings. The transaction was disclosed to the SEC, as required for shareholders owning 10% or more of the company.

Oncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Buys 5,000 Shares

Jorey Chernett, a major shareholder of The Oncology Institute (NASDAQ:TOI), purchased 30,000 shares at $4.09 each, totaling $122,700. This acquisition increased his ownership to 10,529,358 shares, valued at over $43 million. Chernett has made several recent purchases, including 20,000 shares at $3.10 and 125,000 shares at $3.11. Analysts have mixed ratings on TOI, with a consensus price target of $7.00.

Oncology Institute (NASDAQ:TOI) Major Shareholder Jorey Chernett Purchases 30,000 Shares

Oncology Institute major shareholder Jorey Chernett purchased 30,000 shares at $4.09 each, totaling $122,700, increasing his ownership to 10,529,358 shares. This transaction was disclosed to the SEC. Chernett has made several other purchases recently, totaling significant investments in the company. The stock is currently trading at $4.14, with a market cap of $408.70 million.

Insider Buying: Oncology Institute (NASDAQ:TOI) Major Shareholder Buys 30,000 Shares of Stock

Oncology Institute, Inc. reported a strong Q1 2026 with revenues of $147.4 million, up 41.2% year-over-year, driven by specialty pharmacy growth and capitated contracts. Specialty pharmacy revenue surged 77.6% to $87.5 million. Adjusted EBITDA loss narrowed to $2.4 million, with improved cash flow expectations. The Florida market turned profitable, and the company plans to expand its Medicare Advantage lives. However, fee-for-service revenue declined by 10%, and patient services margin compressed to 9.7%. Overall gross margin slightly decreased to 15.8%.

Tip Ranks

Oncology Institute Earnings Call Highlights Growth Pivot

Earnings Watch

Oncology Institute | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 147.44 M

Oncology Institute(TOI.US)